Author

Andy Dzik-Jurasz

Observed names: A Dzik-Jurasz, A. Dzik-Jurasz, A.S.K. Dzik‐Jurasz

Observed institutions: Institute of Cancer Research, Medway NHS Foundation Trust, Medway Maritime Hospital, Novartis (United States)

OpenAlex ID: A5079369601

A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer

2010 · Dana Rathkopf, Bryan Y. Wong, et al. · Cancer Chemotherapy and Pharmacology · 110

Perfusion MR Imaging of Extracranial Tumor Angiogenesis

2004 · Anwar R. Padhani, Andy Dzik-Jurasz · Topics in Magnetic Resonance Imaging · 66

Human rectal adenocarcinoma: Demonstration of 1H‐MR spectra in vivo at 1.5 T

2002 · A.S.K. Dzik‐Jurasz, P.S. Murphy, et al. · Magnetic Resonance in Medicine · 37

Use of biomarkers and imaging to evaluate the treatment effect of AUY922, an HSP90 inhibitor, in patients with HER2+ or ER+ metastatic breast cancer.

2011 · C. P. Schroder, J. V. Pedersen, et al. · Journal of Clinical Oncology · 25

A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx).

2009 · Swaminathan Padmanabhan, Joseph Thaddeus Beck, et al. · Blood · 22

Are targeted contrast agents realistically going to reach the clinic? Recent regulatory experience with targeted MRI contrast agents

2006 · A Dzik-Jurasz · British Journal of Radiology · 4

Imaging in drug development: will it deliver on the promise of personalised medicine?

2010 · A Dzik-Jurasz · British Journal of Radiology · 1

Interstitial cystitis in men

1996 · M. I. Anjum, A. Dzik-Jurasz, et al. · International Urology and Nephrology · 1

The Potential of DW-MRI as an Imaging Biomarker in Clinical Trials

2010 · Andy Dzik-Jurasz, Phil Murphy · Medical radiology

Works count: 9

Citation count: 266

H-index: 5

I10-index: 5